Home  |  Contact
Due to maintenance work, this service and ftp://ftp.expasy.org will be unavailable from Tuesday August 23rd 18:00 until Wednesday August 24th 08:00 CEST. Apologies for the inconvenience.

Cellosaurus LAPC-4 (CVCL_4744)

[Text version]

Cell line name LAPC-4
Synonyms LAPC4; Los Angeles Prostate Cancer-4
Accession CVCL_4744
Resource Identification Initiative To cite this cell line use: LAPC-4 (RRID:CVCL_4744)
Comments Group: Patented cell line.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1441.
Doubling time: ~72 hours; 60.87 hours (https://www.synapse.org/#!Synapse:syn2347014).
Karyotypic information: Has lost chromosome Y.
Omics: Array-based CGH.
Omics: Deep quantitative phosphoproteome analysis.
Omics: Deep RNAseq analysis.
Omics: Transcriptome analysis.
Sequence variations
HLA typing Source: PubMed=25960936
Class I
Disease Prostate carcinoma (NCIt: C4863)
Derived from metastatic site: Lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_4745 (LAPC-4*2 )CVCL_RA56 (LAPC-4-EnzR )CVCL_A0BW (LAPC4-CR )
Sex of cell Male
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): ATCC; PubMed=11304728; PubMed=14518029

D5S81811,13 (PubMed=11304728; PubMed=14518029)
12 (ATCC)
D7S82010,10.3,11 (ATCC)
11 (PubMed=11304728; PubMed=14518029)
D13S3179,10,11,12 (ATCC)
10,12 (PubMed=11304728; PubMed=14518029)
vWA15,16 (ATCC)
16 (PubMed=11304728; PubMed=14518029)

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/LAPC4

PubMed=9095173; DOI=10.1038/nm0497-402
Klein K.A., Reiter R.E., Redula J., Moradi H., Zhu X.L., Brothman A.R., Lamb D.J., Marcelli M., Belldegrun A.S., Witte O.N., Sawyers C.L.
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.
Nat. Med. 3:402-408(1997)

PubMed=10861745; DOI=10.1002/1097-0045(20000601)43:4<263::AID-PROS5>3.0.CO;2-I
van Weerden W.M., Romijn J.C.
Use of nude mouse xenograft models in prostate cancer research.
Prostate 43:263-271(2000)

PubMed=11304728; DOI=10.1002/pros.1045
van Bokhoven A., Varella-Garcia M., Korch C., Hessels D., Miller G.J.
Widely used prostate carcinoma cell lines share common origins.
Prostate 47:36-51(2001)

Sawyers C.L., Klein K.A., Witte O.N., Reiter R.E.
Mice models of human prostate cancer progression.
Patent number US6365797, 02-Apr-2002

PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

PubMed=14518030; DOI=10.1002/pros.10291
van Bokhoven A., Caires A., Maria M.D., Schulte A.P., Lucia M.S., Nordeen S.K., Miller G.J., Varella-Garcia M.
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines.
Prostate 57:226-244(2003)

van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands

PubMed=15486987; DOI=10.1002/pros.20158
Zhao H., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Prostate 63:187-197(2005)

PubMed=15643173; DOI=10.1097/01.ju.0000149989.01263.dc
Sobel R.E., Sadar M.D.
Cell lines used in prostate cancer research: a compendium of old and new lines -- part 2.
J. Urol. 173:360-372(2005)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=28145883; DOI=10.18632/oncotarget.14850
Nouri M., Caradec J., Lubik A.A., Li N., Hollier B.G., Takhar M., Altimirano-Dimas M., Chen M., Roshan-Moniri M., Butler M., Lehman M., Bishop J., Truong S., Huang S.-C., Cochrane D., Cox M., Collins C., Gleave M., Erho N., Alshalafa M., Davicioni E., Nelson C., Gregory-Evans S., Karnes R.J., Jenkins R.B., Klein E.A., Buttyan R.
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Oncotarget 8:18949-18967(2017)

PubMed=29739788; DOI=10.1158/1078-0432.CCR-18-0410
de Leeuw R., McNair C., Schiewer M.J., Neupane N.P., Brand L.J., Augello M.A., Li Z., Cheng L.C., Yoshida A., Courtney S.M., Hazard E.S., Hardiman G., Hussain M.H., Diehl J.A., Drake J.M., Kelly W.K., Knudsen K.E.
MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.
Clin. Cancer Res. 24:4201-4214(2018)

Haffner M.C., Bhamidipati A., Tsai H.K., Esopi D.M., Vaghasia A.M., Low J.-Y., Patel R.A., Guner G., Pham M.-T., Castagna N., Hicks J., Wyhs N., Aebersold R., De Marzo A.M., Nelson W.G., Guo T.-N., Yegnasubramanian S.
Phenotypic characterization of two novel cell line models of castration resistant prostate cancer.
bioRxiv 2021:07.04.450352-07.04.450352(2021)

Cell line collections ATCC; CRL-13009 - Discontinued
Anatomy/cell type resources BTO; BTO:0002997
Biological sample resources BioSample; SAMN03471350
Chemistry resources ChEMBL-Cells; CHEMBL3308023
ChEMBL-Targets; CHEMBL613292
Encyclopedic resources Wikidata; Q29565860
Experimental variables resources EFO; EFO_0005392
Gene expression databases GEO; GSM91931
GEO; GSM648820
GEO; GSM1374616
GEO; GSM1633305
GEO; GSM1633306
GEO; GSM1633307
GEO; GSM2069506
GEO; GSM2069507
GEO; GSM2069508
GEO; GSM2069509
GEO; GSM2069510
GEO; GSM2069511
GEO; GSM2069512
GEO; GSM2069513
GEO; GSM2649999
GEO; GSM2650000
GEO; GSM2650001
GEO; GSM2650002
GEO; GSM2650003
GEO; GSM2650004
GEO; GSM3145715
GEO; GSM5402198
Polymorphism and mutation databases Cosmic; 1330913
Cosmic; 1689711
Cosmic; 2537793
Cosmic; 2580299
IARC_TP53; 18889
Progenetix; CVCL_4744
Proteomic databases PRIDE; PXD006561
Entry history
Entry creation04-Apr-2012
Last entry update23-Jun-2022
Version number27